{"pmid":32292909,"pmcid":"PMC7153514","title":"Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.","text":["Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.","The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.","Med Drug Discov","Liao, Jiayu","Way, George","Madahar, Vipul","32292909"],"abstract":["The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future."],"journal":"Med Drug Discov","authors":["Liao, Jiayu","Way, George","Madahar, Vipul"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292909","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100037","keywords":["COVID-19","Host factor","Influenza virus","SARS-CoV-2","Therapeutics","drug discovery"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["remdesivir"],"_version_":1664266295559847936,"score":8.233237,"similar":[{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663620083139739649,"score":194.16345},{"pmid":32239142,"title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","text":["Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19.","Bioinformatics","Liu, Sen","Zheng, Qiang","Wang, Zhiying","32239142"],"abstract":["MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19."],"journal":"Bioinformatics","authors":["Liu, Sen","Zheng, Qiang","Wang, Zhiying"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239142","week":"202014|Mar 30 - Apr 05","doi":"10.1093/bioinformatics/btaa224","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135477100544,"score":187.48877},{"pmid":32292689,"pmcid":"PMC7102550","title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","text":["Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.","Acta Pharm Sin B","Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua","32292689"],"abstract":["SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections."],"journal":"Acta Pharm Sin B","authors":["Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292689","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.apsb.2020.02.008","keywords":["3CLpro, 3-chymotrypsin-like protease","Drug repurposing","E, envelope","Homology modeling","M, membrane protein","Molecular docking","N, nucleocapsid protein","Nsp, non-structure protein","ORF, open reading frame","PDB, protein data bank","RdRp, RNA-dependence RNA polymerase","Remdesivir","S, Spike","SARS-CoV-2","SUD, SARS unique domain","UB, ubiquitin-like domain"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266295816749057,"score":186.2726},{"pmid":32238094,"title":"Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach.","text":["Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach.","Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs ( Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.","J Biomol Struct Dyn","Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer","32238094"],"abstract":["Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs ( Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery."],"journal":"J Biomol Struct Dyn","authors":["Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238094","week":"202014|Mar 30 - Apr 05","doi":"10.1080/07391102.2020.1751298","keywords":["3CLpro","Drug Repurposing","MD Simulation","Remdesivir","SARS-CoV-2","virtual screening,corona viru"],"source":"PubMed","locations":["Chymotrypsin","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Coumarins","remdesivir","Saquinavir","flavone","Darunavir"],"_version_":1663352135603978240,"score":168.58784},{"pmid":32201449,"pmcid":"PMC7074424","title":"Drug targets for corona virus: A systematic review.","text":["Drug targets for corona virus: A systematic review.","The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs.","Indian J Pharmacol","Prajapat, Manisha","Sarma, Phulen","Shekhar, Nishant","Avti, Pramod","Sinha, Shweta","Kaur, Hardeep","Kumar, Subodh","Bhattacharyya, Anusuya","Kumar, Harish","Bansal, Seema","Medhi, Bikash","32201449"],"abstract":["The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs."],"journal":"Indian J Pharmacol","authors":["Prajapat, Manisha","Sarma, Phulen","Shekhar, Nishant","Avti, Pramod","Sinha, Shweta","Kaur, Hardeep","Kumar, Subodh","Bhattacharyya, Anusuya","Kumar, Harish","Bansal, Seema","Medhi, Bikash"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201449","week":"202013|Mar 23 - Mar 29","doi":"10.4103/ijp.IJP_115_20","keywords":["*Coronavirus","*Middle East respiratory syndrome","*drug targets","*severe acute respiratory syndrome"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Serine"],"_version_":1663352133678792705,"score":164.187}]}